Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 17/20 | 0.83 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183476 | 0.92 | LTB4R2 (0.82) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18425728 | 0.91 | LTB4R2 (1.00) | LTB4R2PTGDR2 | |
| SCHEMBL20183539 | 0.89 | LTB4R2 (0.80) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18425739 | 0.89 | LTB4R2 (0.93) | LTB4R2PTGDR2 | |
| SCHEMBL18425423 | 0.87 | LTB4R2 (0.78) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18425267 | 0.86 | LTB4R2 (1.00) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL20183485 | 0.84 | LTB4R2 (0.76) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL20183579 | 0.84 | LTB4R2 (0.79) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL28229584 | 0.83 | LTB4R2 (0.85) | LTB4R2 | |
| SCHEMBL18424852 | 0.82 | LTB4R2 (0.76) | LTB4R2PTGDR2CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| CN-108349875-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-08-27 | — | — | CN | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | LTB4R2 1/4885PTGDR2 43/4885CYP2C8 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.